Skip to content
Prescription / GLP-1tirzepatide pills

Tirzepatide Pills: Is There an Oral Tirzepatide? What Exists

There is no FDA-approved tirzepatide pill. What oral tirzepatide sellers offer, the trial data, and Lilly's Foundayo pill, with prices as of 3 October 2026.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

There is no FDA-approved tirzepatide pill. Every approved tirzepatide product is a weekly injection, sold by Eli Lilly as Zepbound or Mounjaro. The GLP-1 pill Lilly does sell is Foundayo, a different drug called orforglipron. It costs $149 to $299 a month self-pay with on-time refills (3 October 2026). "Oral tirzepatide" sold online is compounded, usually a tablet or drop held under the tongue, and not FDA-approved. I found no peer-reviewed human trial showing that any oral form works.

  • FDA lists only two tirzepatide products, Mounjaro and Zepbound, and both are injections.
  • Lilly's approved GLP-1 pill is Foundayo (orforglipron), a different molecule: $149 to $299 a month self-pay with on-time refills (3 October 2026).
  • Oral tirzepatide from telehealth sellers is compounded, not FDA-approved, and usually a tablet or drop held under the tongue.
  • The only human study of an oral tirzepatide capsule I found, reported by its maker, showed no average weight loss after 12 weeks.
  • In May 2026 FDA proposed keeping tirzepatide off the 503B bulks list, finding no clinical need for compounded oral or under-the-tongue forms.

There is no FDA-approved tirzepatide pill. As of 3 October 2026, every approved tirzepatide product is a weekly injection, sold by Eli Lilly as Zepbound or Mounjaro.

The GLP-1 pill Lilly does sell is Foundayo, a different drug called orforglipron. Lilly charges $149 to $299 a month for it without insurance, with on-time refills.

Tirzepatide sold as tablets or drops is compounded, and none of it has been through FDA review. I found no peer-reviewed human trial showing that any oral form works.

Is there an FDA-approved tirzepatide pill?

No. I checked three sources on 3 October 2026:

  • Drugs@FDA. FDA’s drug database lists two tirzepatide applications, both Eli Lilly’s: Mounjaro and Zepbound. Every product under them is a solution for injection under the skin.
  • DailyMed. The national label library holds 8 tirzepatide labels. All are for injection: Lilly’s two, plus 6 repackaged Mounjaro labels.
  • Lilly’s pipeline. Its tirzepatide entries are new uses, higher doses and combinations with other drugs. None describes an oral form.

FDA said the same in a notice published on 1 May 2026: “no tirzepatide drug product is approved in these routes of administration”. The routes were oral, sublingual (under the tongue) and buccal (inside the cheek).

What is Lilly’s GLP-1 pill?

Lilly’s pill is Foundayo, the brand name for orforglipron. FDA approved it on 1 April 2026 for long-term weight management in adults with obesity, or overweight plus a weight-related condition. It is taken once a day, with or without food.

Foundayo is not a tablet form of tirzepatide:

  • Different molecule. Orforglipron is a small molecule, not a peptide, which is why it survives being swallowed.
  • Different target. It activates the GLP-1 receptor only. Tirzepatide activates both the GIP and GLP-1 receptors.
  • Different trials. On its label, weight fell 11.1% on the top 17.2 mg dose over 72 weeks, against 2.1% on placebo. On the Zepbound label, it fell 20.9% on 15 mg over 72 weeks, against 3.1%. These were separate trials in different people, and neither label reports a head-to-head comparison.

Prices, doses and side effects: Foundayo. The molecule and its approval: orforglipron.

Tirzepatide pills vs the approved options

Prices are from Lilly, Novo Nordisk and TrumpRx.gov, checked on 3 October 2026. Every approved product needs a prescription.

ProductFormFDA statusPrice, 3 October 2026
Zepbound (tirzepatide), Eli LillyWeekly injectionApproved for weight management, and sleep apnoea with obesity$299 to $449 a month self-pay for vials or KwikPen, with refills within 45 days
Mounjaro (tirzepatide), Eli LillyWeekly injectionApproved for type 2 diabetes, including lowering heart risk$499 a month self-pay, any strength
Foundayo (orforglipron), Eli LillyDaily tabletApproved 1 April 2026 for weight management$149 to $299 a month self-pay with on-time refills; $349 at the top two doses if a refill is late
Wegovy pill (semaglutide), Novo NordiskDaily tabletApproved for weight management$149 to $299 a month self-pay, by dose
Compounded “oral tirzepatide”Tablet or drops held under the tongue, or a dissolving tabletNot FDA-approved; made by a pharmacy for one patient’s prescriptionSet by each seller; not tracked here

Lilly’s list prices, before insurance, are $499 to $1,086.37 per fill for Zepbound and $649 a month for Foundayo. The Foundayo prices at 2.5 mg and 5.5 mg are temporary reductions that run to 31 December 2026. Every option, with insurance and Medicare: tirzepatide, Zepbound, Foundayo and Wegovy.

Why tirzepatide is an injection

Tirzepatide is a peptide, a chain of amino acids based on the gut hormone GIP. Peptides are hard to absorb from the gut. Researchers trying to make a tirzepatide tablet list poor absorption through the gut wall first among the problems (Im 2026 - Im S, Lee JY, Kim JE. Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets. Pharmaceutics. 2026;18(7)., in the references below).

The approved semaglutide tablet shows how hard this is. The Wegovy pill needs an absorption enhancer called SNAC, and its label puts oral bioavailability at about 1% to 2%, against 89% by injection. It must be swallowed whole on an empty stomach, with no more than 4 ounces of water, at least 30 minutes before food.

Injected tirzepatide has a mean bioavailability of 80%, per the Zepbound label. I found no published human measure of how much tirzepatide reaches the blood from a compounded tablet or drop held under the tongue.

What is “oral tirzepatide” from telehealth and compounding pharmacies?

It is tirzepatide made up by a compounding pharmacy as a tablet or liquid. The common forms are:

  • Sublingual tablets or drops, held under the tongue until absorbed;
  • Orally disintegrating tablets, which dissolve in the mouth.

Studies of the US market have found them on sale:

On 3 October 2026, two of Google’s top 10 results for “tirzepatide pills” were pages for these products. One was a telehealth store selling tirzepatide drops for under the tongue. Its page says absorption by mouth varies from person to person, and that injections may work better for some. The other was a clinic page for dissolving tablets, which now says it no longer offers compounded tirzepatide.

All of these need a prescription. Compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness or quality before sale.

What FDA has said about compounded oral tirzepatide

FDA addressed oral tirzepatide directly in a notice published on 1 May 2026. Nominations had asked FDA to let outsourcing facilities (503B) compound tirzepatide from bulk powder, including as oral, sublingual and buccal products.

FDA proposed to say no. It found no basis to conclude that the approved injections are medically unsuitable for some patients. It also found no basis to think an oral or under-the-tongue product would fix such a problem. It added that the legal standard is clinical need, not preference. The comment period was extended to 30 July 2026. As of 3 October 2026, I found no final decision in the Federal Register.

That proposal covers outsourcing facilities. Under the separate 503A route, a state-licensed pharmacy can still compound tirzepatide for an individual patient’s prescription, within limits:

  • A pharmacy may not regularly compound “essentially a copy” of an approved drug. FDA treats a compounded drug as one when it has the same active ingredient at a similar strength and the approved drug can be used by the same route.
  • On 18 September 2026, FDA applied that test in a warning letter to Empower Pharmacy. It found that tirzepatide products made with niacinamide, a form of vitamin B3, appeared to be essentially copies of the approved drugs.
  • No approved tirzepatide is taken by mouth.
  • I found no FDA statement applying that test to oral tirzepatide.

FDA has acted on how compounded GLP-1 drugs are sold. On 6 February 2026, it said sellers cannot call them generic or the same as approved drugs. Nor can they say the products use the same active ingredient, or are clinically proven. On 3 March 2026, it announced warning letters to 30 telehealth companies over claims of sameness.

I found no FDA warning letter aimed specifically at an oral or under-the-tongue tirzepatide product. The nearest is a letter of 9 September 2025 to Elevated, an online seller of compounded semaglutide and tirzepatide. FDA cited its claim that a dissolving semaglutide tablet delivers the same active ingredient as the leading GLP-1 medicines.

As of 31 May 2026, FDA had received more than 730 adverse event reports linked to compounded tirzepatide. Its count does not say how many involved oral forms. Compounded and branded tirzepatide compared, including how the shortage rules ended: compounded GLP-1 pricing.

Does oral tirzepatide work?

Limited human data

Small or uncontrolled human studies. Too little to settle the question either way. One small study of an experimental oral tirzepatide capsule, run by its maker and reported only by press release, found no average weight loss after 12 weeks. I found no study of the compounded under-the-tongue tablets or drops, and no peer-reviewed human trial of any oral tirzepatide.

I searched PubMed on 3 October 2026 and found no published human trial of oral tirzepatide. What exists:

The Lexaria results come from press releases, not a peer-reviewed paper, and its capsule is not what telehealth sellers offer. The authors of the search of compounding sites saw a rationale for under-the-tongue and dissolving forms. They said it has not been shown whether these forms offer any advantage over the approved tablets. They called the products’ popularity concerning, given the lack of safety and efficacy evidence (Belcourt 2026 - Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother. 2026;60(9):902-906., in the references below).

Oral tirzepatide vs the injection

Compared onZepbound or Mounjaro injectionCompounded oral tirzepatide
FDA reviewApproved, with a labelNone
Dose2.5 mg once a week, rising in 2.5 mg steps to 5, 10 or 15 mg (Zepbound)No label dose; strengths set by the pharmacy
How much reaches the blood80% on averageNot published
Weight-loss evidence72-week trials: 15% to 20.9% average loss by dose, against 3.1% on placebo (Zepbound)No trials found
Price, 3 October 2026Zepbound $299 to $449 a month self-pay; Mounjaro $499Set by each seller

The safety warnings on the tirzepatide label, including the boxed warning on thyroid C-cell tumours, apply to the drug itself, whatever the form. The approved drug, its doses and side effects: tirzepatide and tirzepatide dosage. The legal ways to get it online: tirzepatide online.

Research-labelled tirzepatide: not a pill, and not the approved medicine

These are research-use products, not Zepbound or Mounjaro. On 3 October 2026 I checked the full catalogues of the three active sellers in our vendor registry. None sells tirzepatide as a tablet, capsule or drops. Two sell it in vials labelled for research.

SellerProduct, as soldSizes and prices, 3 October 2026What our review found
Next Level Pharm“Tirzep GLP-2” vial, freeze-dried powder5 mg $30.99, 10 mg $56.99, 15 mg $69.99, 20 mg $82.99, 30 mg $102.99, 40 mg $111.99, 50 mg $119.99, 60 mg $128.99, 80 mg $158.99 (sale prices)Names its testing lab; batch certificate checkable on the lab’s own portal; no FDA warning letter found (review)
Spartan Peptides“GLP-2(Tirz)” vial, a code name10 mg $250Signed lab reports for 6 compounds, all on one lot code; no FDA warning letter found (review)

BioEdge Research Labs sells no tirzepatide product. Peptide Decode has no commercial relationship with any of these sellers and earns nothing from these links.

How these differ from Zepbound and Mounjaro:

  • No FDA review. They have not been through the review behind the tirzepatide labels.
  • Labelled not for human use. Both product pages say so.
  • Testing chosen by the seller. Which batches are tested, and by whom, is up to each vendor.

FDA has acted against research-labelled tirzepatide. Warning letters to Summit Research Peptides (10 December 2024) and Royal Peptides (24 August 2026) found the tirzepatide products to be unapproved new drugs. Royal Peptides labelled its products for research use only; FDA said the evidence showed they were intended for human use. I found no warning letter to the three sellers in our registry.

This page gives no dosing for research vials. Dosing for approved tirzepatide comes from its FDA label: tirzepatide dosage. What a certificate of analysis can show: how to read a peptide COA.

Common questions

Does tirzepatide come in pill form?

Not as an FDA-approved medicine. On 3 October 2026, FDA's Drugs@FDA data listed two tirzepatide products, Mounjaro and Zepbound, and every version of both is an injection under the skin. Tablets and drops sold as tirzepatide are compounded, and none has been through FDA review.

When will tirzepatide pills be available?

I found no sign of one coming from Lilly. Its published pipeline, checked on 3 October 2026, lists new uses and higher doses of tirzepatide but no oral form. Lilly's pill programme is orforglipron, approved as Foundayo on 1 April 2026. One other company, Lexaria Bioscience, has tested an experimental tirzepatide capsule in people.

Does oral tirzepatide actually work?

I found no peer-reviewed human trial showing that it does. The one human study of an oral tirzepatide capsule I found was run by its maker, Lexaria Bioscience, and reported by press release. After 12 weeks, the 25 people on it had gained 0.67 kg on average. I found no study at all of the compounded under-the-tongue tablets or drops sold by telehealth companies.

Is oral tirzepatide more effective than injected tirzepatide?

I found no evidence that it is. Injected tirzepatide has 72-week trials behind it: average weight fell 15% to 20.9% by dose on the Zepbound label, against 3.1% on placebo. I found no trial comparing oral and injected tirzepatide. I also found no published measure of how much tirzepatide reaches the blood from a compounded tablet or drop.

Do oral tirzepatide drops work?

I found no evidence that they do. I found no study measuring how much tirzepatide gets into the blood from drops under the tongue, or whether they cause weight loss. One telehealth seller of the drops says on its own page that absorption by mouth varies from person to person. It adds that injections may work better for some.

Is Foundayo the same as tirzepatide?

No. Foundayo is orforglipron, a small molecule that activates the GLP-1 receptor. Tirzepatide is a peptide that activates both the GIP and GLP-1 receptors, sold as the Zepbound and Mounjaro injections. Both are made by Eli Lilly, but they are different drugs with different labels and trials, and neither label reports a head-to-head trial.

Is semaglutide available in tablet form?

Yes. FDA has approved semaglutide tablets as the Wegovy pill for weight management, and as Rybelsus and the Ozempic pill for type 2 diabetes. As of 3 October 2026, Novo Nordisk sells the Wegovy pill self-pay for $149 to $299 a month, by dose. The Wegovy pill contains an absorption enhancer and must be swallowed whole on an empty stomach.

What are the brand names for tirzepatide?

Mounjaro and Zepbound, both made by Eli Lilly. They contain the same drug in the same strengths. They differ in what each is approved for. Mounjaro is for type 2 diabetes, including lowering heart-attack and stroke risk in high-risk adults who have it. Zepbound is for weight management and obstructive sleep apnoea in adults with obesity. Neither comes as a pill.

How does tirzepatide work for weight loss?

It activates two gut-hormone receptors, GIP and GLP-1, which are also found in brain areas that control appetite. The Zepbound label says it decreases calorie intake, likely by affecting appetite, and lowers weight with more fat lost than lean mass. A fatty acid chain binds it to a blood protein, giving a half-life of about 5 days, so it is injected once a week.

Is compounded oral tirzepatide legal?

A state-licensed pharmacy can compound tirzepatide for one patient's prescription, but the product is not FDA-approved and FDA does not review it. Pharmacies may not regularly compound copies of an approved drug. FDA's test for a copy includes whether the approved drug is used by the same route, and no approved tirzepatide is taken by mouth. I found no FDA statement applying that test to oral tirzepatide. In May 2026, FDA proposed keeping tirzepatide off the list outsourcing facilities can compound from.

How much do tirzepatide pills cost?

There is no approved tirzepatide pill to price. Compounded versions are priced by each seller, and I do not track those. As of 3 October 2026, the approved alternatives cost this much. Lilly's Foundayo pill is $149 to $299 a month self-pay with on-time refills. Zepbound vials or KwikPens are $299 to $449 a month self-pay with refills within 45 days.

What is the #1 weight loss pill?

There is no official ranking. The two FDA-approved GLP-1 pills for weight management are the Wegovy pill and Foundayo. On their labels, weight fell 13.6% on the 25 mg Wegovy pill over 64 weeks, against 2.4% on placebo. It fell 11.1% on 17.2 mg Foundayo over 72 weeks, against 2.1%. These were separate trials, so the figures cannot be compared directly.

Can you buy tirzepatide capsules?

Not as an approved medicine. No tirzepatide capsule is FDA-approved, and none of the three research vendors I check sells one (3 October 2026). The only tirzepatide capsule I found tested in people was an experimental one from Lexaria Bioscience, and its 12-week study showed no average weight loss.

References (36 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother. 2026;60(9):902-906.StudyPMID 41689811
  2. 2.DiStefano MJ, Tilley A, Paratane D et al. Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. JAMA Health Forum. 2026;7(7):e262207.StudyPMID 42467450
  3. 3.DiStefano MJ, Dardouri M, Moore GD et al. Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. J Pharm Policy Pract. 2025;18(1):2441220.StudyPMID 39776466full text
  4. 4.Im S, Lee JY, Kim JE. Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets. Pharmaceutics. 2026;18(7).StudyPMID 42514904full text
  5. 5.Zhang Y, Han J, Wu W et al. Oral Delivery of Semaglutide and Tirzepatide Using Milk-Derived Small Extracellular Vesicles. J Extracell Biol. 2025;4(11):e70099.StudyPMID 41293773full text
  6. 6.openFDA Drugs@FDA query for tirzepatide: two applications, both Eli Lilly NDAs (Mounjaro and Zepbound), every product a solution for subcutaneous injection, checked 3 October 2026.- US Food and Drug Administration (openFDA)database
  7. 7.DailyMed search for tirzepatide: 8 labels, all injection, solution (Lilly's Zepbound and Mounjaro labels plus 6 repackaged Mounjaro labels), checked 3 October 2026.- DailyMed, National Library of Medicinedatabase
  8. 8.ZEPBOUND (tirzepatide) injection - prescribing information: subcutaneous use only, peptide structure, 80% bioavailability after injection, dose escalation and 72-week weight results.- DailyMed, National Library of Medicinelabel
  9. 9.MOUNJARO (tirzepatide) injection - prescribing information: indications (type 2 diabetes, and lowering major cardiovascular risk in high-risk adults with type 2 diabetes), subcutaneous use.- DailyMed, National Library of Medicinelabel
  10. 10.Eli Lilly research pipeline: tirzepatide entries (new uses, higher doses and combinations, no oral form; classed as a large molecule) and orforglipron entries (classed as a small molecule), checked 3 October 2026.- Eli Lilly and Companyother
  11. 11.FOUNDAYO (orforglipron) tablets - prescribing information: GLP-1 receptor agonist, once daily with or without food, 72-week weight results.- DailyMed, National Library of Medicinelabel
  12. 12.FDA news release (1 April 2026): FDA approves Foundayo (orforglipron) for weight management, the first new molecular entity under the National Priority Voucher programme.- US Food and Drug Administrationregulatory
  13. 13.Lilly: Foundayo coverage and savings - self-pay prices by dose, temporary reductions through 31 December 2026 and the 45-day refill offer, checked 3 October 2026.- Eli Lilly and Companyother
  14. 14.Lilly: Foundayo cost information - list price (WAC) of $649 for a 30-day supply, checked 3 October 2026.- Eli Lilly and Companyother
  15. 15.Lilly: Zepbound cost information - list price range per fill and self-pay prices by dose for vials and KwikPens, checked 3 October 2026.- Eli Lilly and Companyother
  16. 16.Lilly: Zepbound savings - the $299 starting self-pay price and the $449 offer for refills within 45 days, checked 3 October 2026.- Eli Lilly and Companyother
  17. 17.TrumpRx: Mounjaro listing - $499 self-pay price at every strength, ordered through LillyDirect, checked 3 October 2026.- TrumpRx.gov (US government)other
  18. 18.WEGOVY (semaglutide) injection and tablets - prescribing information: SNAC absorption enhancer, oral bioavailability of about 1% to 2%, swallow-whole rules and the 64-week tablet trial.- DailyMed, National Library of Medicinelabel
  19. 19.Novo Nordisk: what to pay for Wegovy - self-pay prices for the Wegovy pill by dose, checked 3 October 2026.- Novo Nordiskother
  20. 20.NovoCare: Rybelsus - Rybelsus is being replaced by the Ozempic pill for type 2 diabetes, checked 3 October 2026.- Novo Nordiskother
  21. 21.Federal Register, 1 May 2026: FDA proposes not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, including its review of proposed oral, sublingual and buccal tirzepatide.- Federal Register (US Food and Drug Administration)regulatory
  22. 22.Federal Register, 26 June 2026: FDA extends the comment period on the 503B GLP-1 proposal to 30 July 2026.- Federal Register (US Food and Drug Administration)regulatory
  23. 23.FDA news release (30 April 2026): FDA proposes to exclude semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding no clinical need.- US Food and Drug Administrationregulatory
  24. 24.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated 1 April 2026): 503A prescriptions, the essentially-a-copy test by route, and 503B limits.- US Food and Drug Administrationregulatory
  25. 25.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (updated 1 October 2026): compounded drugs are not reviewed, adverse event counts, and research-labelled GLP-1 products.- US Food and Drug Administrationregulatory
  26. 26.FDA statement, 6 February 2026: FDA intends to restrict GLP-1 ingredients for mass-marketed compounded drugs, and limits claims of sameness, same active ingredient or clinical proof.- US Food and Drug Administrationregulatory
  27. 27.FDA news release, 3 March 2026: warning letters to 30 telehealth companies over claims of sameness and obscured sourcing for compounded GLP-1 drugs.- US Food and Drug Administrationregulatory
  28. 28.Lexaria Bioscience news release, 24 February 2025: ethics approval for arm 5 of study GLP-1-H24-4, DehydraTECH-tirzepatide capsules.- Lexaria Bioscience Corp.news
  29. 29.Lexaria Bioscience news release, 23 December 2025: 12-week phase 1b study GLP-1-H24-4 in Australia, including body weight and HbA1c in the DehydraTECH-tirzepatide capsule arm.- Lexaria Bioscience Corp.news
  30. 30.Lexaria Bioscience news release, 30 December 2025: further results from study GLP-1-H24-4, including plasma tirzepatide levels in the capsule arm.- Lexaria Bioscience Corp.news
  31. 31.FDA warning letter to Elevate Your Wellness LLC (Elevated), 9 September 2025: claims for compounded semaglutide and tirzepatide, including a "Semaglutide ODT" dissolvable tablet, cited as false or misleading.- US Food and Drug Administrationregulatory
  32. 32.FDA warning letter to Empower Pharmacy, 18 September 2026: compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products appear to be essentially copies of the approved drugs.- US Food and Drug Administrationregulatory
  33. 33.FDA warning letter to Royal Peptides LLC, 24 August 2026: research-labelled tirzepatide, semaglutide and retatrutide found to be unapproved new drugs.- US Food and Drug Administrationregulatory
  34. 34.FDA warning letter to Summit Research Peptides, 10 December 2024: tirzepatide, semaglutide and other GLP-1 products found to be unapproved new drugs.- US Food and Drug Administrationregulatory
  35. 35.Next Level Pharm: "Tirzep GLP-2" product page - vial sizes, sale prices and labelling as not intended for human use, checked 3 October 2026.- Next Level Pharmother
  36. 36.Spartan Peptides: "GLP-2(Tirz)" product page - 10 mg vial price and labelling as research use only, not for human consumption, checked 3 October 2026.- Spartan Peptidesother

Keep reading

Related guides